最新ニュース Beyond Air (NASDAQ:XAIR) 株価情報

Beyond Air

Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.

Beyond Air Inc

NIP Group Inc. ("NIP Group" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIPG#NASDAQ">NIPG</a>), a leading digital entertainment company, today announced a major expansion of its live entertainment business through the formation of NIP Culture &amp; Entertainment (Beijing) Co., Ltd. ("NIP Culture &amp; Entertainment"), a new joint venture formed to expand NIP Group's live entertainment footprint across the Chinese market. This strategic initiative significantly extends the Company's capabilities beyond its core esports business, adding large-scale music festival production to its portfolio. The venture is designed to capture new opportunities in the broader live entertainment and cultural experiences market and further diversify NIP Group's revenue streams.
The new venture made a high-impact debut with the 2025QianfanMusicSeason - WonderlandMusicFestival, attracting over 70,000 fans. The two-day festival, held in Beijing from May 31 through June 1, set a new record as one of the largest single-site outdoor music festivals ever hosted in the city. NIP Culture &amp; Entertainment's inaugural flagship event introduced a distinctive vibe, blending performances from 19 leading musicians with appearances by championship esports teams eStar Pro and Beijing WB. Curated food, immersive creative markets and localized experiences showcasing Beijing's attractions extended the entertainment footprint well beyond the stage and demonstrated NIP Group's ability to orchestrate large-scale, cross-format experiences that resonate with younger audiences.

News

Global

NIPG

NIP Group Expands Into China's Live Entertainment Market With New JV, NIP Culture & Entertainment (Beijing) Co., Ltd.

Fold Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLD#NASDAQ">FLD</a>) ("Fold" or the "Company"), the first publicly traded bitcoin financial services company, today announced that it has entered into an agreement for a $250 million equity purchase facility ("Facility"), with the net proceeds primarily intended to be used to acquire additional bitcoin for Fold's corporate treasury.
Pursuant to the Facility, the Company, in its sole discretion, has the right, but not the obligation, to issue and sell up to $250 million in newly issued shares of the Company's common stock ("Common Stock"), subject to certain conditions, including that a registration statement covering the resale of the Common Stock be filed and declared effective by the Securities and Exchange Commission ("SEC"). The Company is not required to use the Facility and controls the timing and amount of any drawdown on the Facility, subject to certain restrictions under the Facility. The Company expects to use the net proceeds from the Facility, if any, primarily to acquire additional bitcoin for Fold's corporate treasury.

Fold Holdings Enters Into Agreement For $250M Equity Purchase Facility, With Net Proceeds Primarily Intended To Be Used To Acquire Additional Bitcoin For Fold's Corporate Treasury

AGRI

AgriFORCE Commissions Power & Compute Site In Alberta; Co. Also Executes LOI With BlueFlare Energy To Acquire Up To 1.3 MW Of Compute Infrastructure Across Alberta

Electrified Materials Secures State Grant to Advance Rare Earth and Critical Mineral Recycling in Indiana
FISHERS, IN / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 17, 2025 / American Resources Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREC#NASDAQ">AREC</a>) ("American Resources") today announced that its wholly owned subsidiary, Electrified Materials Corporation ("Electrified Materials" or "EMCO"), has finalized and signed all agreements related to a $911,519 matching grant awarded through the Indiana Department of Environmental Management's Waste Diversion Project.
This funding will support the purchase of advanced equipment for the preprocessing and recycling of rare earth magnets, critical minerals, and defense materials. The materials will be refined by ReElement Technologies Corporation ("ReElement") as part of a broader effort to establish a collaborative, circular supply chain and help reshore this vital industry to the United States.
Electrified Materials currently has access to a 135-acre site in Noblesville, Indiana, where it will expand its operations focused on end-of-life rare earth magnets, lithium-ion batteries, and defense metals-further supporting national security and sustainable domestic production.

Contracts

AREC

Electrified Materials Secures $911,519 Indiana State Grant To Expand Rare Earth And Critical Mineral Recycling Operations

Lipella Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today announced the issuance of U.S. Patent No. 12,326,492, titled "Systems and Methods of Detecting Interstitial Cystitis." The patent was issued by the United States Patent and Trademark Office on June 10, 2025, and provides protection through at least 2045, subject to potential extensions.
The patent covers a method, using magnetic resonance imaging (MRI), to detect lesions (or permeability defects) in body cavities. "This method can potentially provide enhanced outcome assessments to our development programs; especially mucosal disorders, including our existing programs: LP-310 for oral lichen planus, LP-10 for hemorrhagic cystitis and LP-50 for bladder cancer." said Dr. Michael Chancellor, Chief Medical Officer.
"This patent strengthens Lipella's strategic position in drug delivery," said Jonathan Kaufman, Chief Executive Officer. "The ability to non-invasively monitor the progression (or regression) of body cavity lesions, using a novel MRI contrast agent, will not only enhance our existing clinical development efforts, but can itself become a clinically-relevant early detection tool."
 &nbsp;

Biotech

General

LIPO

Lipella Pharmaceuticals Announces U.S. Patent Titled "Systems And Methods Of Detecting Interstitial Cystitis." Has Been Issued For Its Diagnostic Technology

Meiwu Technology Agrees With Shenzhen Zhinuo Weichuang Technology To Enhance Brand Influence And Market Competitiveness

Stardust Power Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDST#NASDAQ">SDST</a>) (the "Company"), an American developer of battery-grade lithium products, today announced the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $4.3 million, before deducting underwriting fees and other offering expenses payable by the Company.
The offering consists of 21,500,000 shares of common stock ("Common Stock"). The public offering price per share of Common Stock is $0.20.
In addition, the Company has granted Aegis Capital Corp. ("Aegis") a 45-day option to purchase additional shares of Common Stock of up to 15.0% of the number of shares of Common Stock sold in the offering solely to cover over-allotments, if any.
Aggregate gross proceeds to the Company are expected to be approximately $4.3 million. The transaction is expected to close on or about June 18, 2025, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the offering, together with its existing cash, for general corporate purposes and working capital.

Offerings

SDST

Stardust Power Prices $4.3M Public Offering Of 21.5M Shares At A Price Of $0.20 Per Share

WIIM

BKYI

BKYI stock has given up its prior gain. BIO-key shares were trading higher after the company received over $600K in follow-on orders from an international defense ministry.

STRL

Sterling To Acquire CEC Facilities Group For Purchase Price At Closing Of $505M; Estimates CEC Full-Year Revenues $390M-$415M

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ftortoisecapital.com%2F&amp;esheet=54277106&amp;newsitemid=20250617696540&amp;lan=en-US&amp;anchor=Tortoise+Capital+Advisors%2C+L.L.C.&amp;index=1&amp;md5=8ad01c97389b5dc333ac99526efcca93">Tortoise Capital Advisors, L.L.C.</a> (Tortoise Capital), a fund manager focused on energy investing, today announced plans to merge two of its closed-end funds.
The board of directors of each of Tortoise Sustainable and Social Impact Term Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEAF#NYSE">TEAF</a>) and Tortoise Energy Infrastructure Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYG#NYSE">TYG</a>) have approved the merger of TEAF into TYG, with TYG as the surviving company. This strategic merger is designed to enhance scale, improve efficiency, and strengthen Tortoise Capital's leadership in energy infrastructure investing – while better serving shareholders.
As of May 31, 2025, the combined total assets under management of TYG and TEAF are approximately $1.2 billion. TYG will retain its existing investment strategy and objective, continuing as Tortoise Capital's sole closed-end fund for investors seeking long-term exposure to essential energy assets.
TYG provides diversified exposure to energy and power infrastructure and seeks a high level of total return with an emphasis on current distributions. TYG's investment strategy is designed to capitalize on the ‘age of electricity,' driven by data center growth, electrification, and grid modernization as well as unprecedented natural gas and LNG demand as a globally scalable, lower-emission fuel anchoring U.S energy exports. The board of TYG also approved a 30% increase in distributions for TYG, subject to and upon completion of the merger.

TEAF

Tortoise Capital Merges TEAF Into TYG, Strengthening Energy Infrastructure Focus

QUBT

Quantum Computing Inc.Announces The Shipment Of Commercial Entangled Photon Source

CPAY

Corpay's Cross-Border Business Enters Into Multi-Year Agreement To Extend Exclusive Collaboration With West Ham United As Official FX And International Payments Partner

MBOT

Microbot Medical  Granted China Patent

SGRY

Surgery Partners shares are trading lower. The com reaffirmed its FY25 guidance.

When a single mom regained custody of her son after a stint in the foster care system and various inpatient facilities for behavioral concerns, she thought things would finally settle down. But nearly a year later, she discovered something unexpected — someone else had still been receiving her child's monthly Supplemental Security Income payments.
The situation has raised questions about how <a href="https://www.benzinga.com/personal-finance/25/05/45484124/theyll-take-away-my-benefits-if-i-move-in-with-you-why-one-disabled-mom-fears-living-with-her-adult-child">disability benefits</a> are handled for children in state care, and what happens when they return to their families.
Don't Miss:
<ul class="wp-block-list">
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – Many are rushing to <a href="https://www.benzinga.com/money/mode-mobile-2">grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
<h2 class="wp-block-heading">A Trail of $30 Payments</h2>
The mother, who shared her story anonymously on a <a href="https://www.reddit.com/r/SocialSecurity/comments/1l4uehi/wasnt_made_aware_my_son_was_approved_for_ssdi/">Reddit forum</a> dedicated to Social Security issues, explained that she temporarily lost custody of her 10-year-old son. Due to behavioral challenges, he couldn't be placed with a stable foster family and was eventually sent to an inpatient psychiatric facility, where he remained for close to a year.
He was discharged and returned home in July 2024. But it wasn't until months later — while applying for food assistance — that the mother learned her son was receiving $30 per month in unearned income. She hadn't known anything about him being approved for SSI during his time away.
"I was clueless," she wrote. After speaking with her old caseworker, she got little clarity. It wasn't until March that she received a letter from the <a href="https://www.benzinga.com/25/05/45279374/social-security-goes-digital-americans-will-soon-access-their-numbers-online-as-ssa-unveils-modern-alternative-to-paper-cards">Social Security Administration</a>, informing her she needed to apply to become her son's representative payee — someone who manages benefits on behalf of someone else.
She completed the interview and submitted paperwork in April. But by early June, she still hadn't received any updates, despite several follow-up calls to her local SSA office.
Trending: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
<h2 class="wp-block-heading">Why Was the Facility Still Getting Paid?</h2>
According to <a href="https://www.ssa.gov/pubs/EN-05-10026.pdf">SSA rules</a>, when a child is in a medical institution — and Medicaid or another insurance program is covering the cost — their SSI payment is usually capped at $30 per month. This payment may go to the facility directly to help cover any incidental costs of care.
In this case, even though the boy had left the facility in July 2024, records show someone continued receiving the $30 monthly payment for at least another eight months after he was reunified with his mother.
"If I had kept getting his benefits after he left my care, I'd be in big trouble," the mom noted. Now she's asking whether she's entitled to any of those missed funds.
<h2 class="wp-block-heading">Next Steps and Unanswered Questions</h2>
The mother has since been approved to act as her son's representative payee, and was told the monthly benefit will increase now that he lives at home. But delays at the Social Security office have left her frustrated.
See Also: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>
Online commenters pointed out that the facility may have applied for SSI to qualify the child for specialized Medicaid coverage — not uncommon in these situations. Others advised the mother to contact the SSA directly to report the overpayment and clarify her son's eligibility moving forward.
It remains to be seen whether she'll receive back pay for the months he was home but not receiving his benefits. The SSA has procedures in place to recover or redirect funds if a payee receives money they're no longer entitled to — but how that plays out in this case is unclear.
<h2 class="wp-block-heading">What Families Can Learn</h2>
This story highlights how important it is for parents and guardians to stay informed about any government benefits their children may qualify for — especially when custody arrangements change. It also underscores how complex navigating systems like <a href="https://www.benzinga.com/personal-finance/25/05/45665342/social-security-is-the-main-source-of-income-for-retirees-in-these-10-states-is-your-state-on-the-list">Social Security</a> can be, even for those doing everything by the book.
If you're in a similar situation, the SSA encourages you to contact your local office or visit ssa.gov to learn more about representative payees and SSI eligibility.&nbsp;
Read Next:
<ul class="wp-block-list">
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/how-peter-thiel-turned-his-roth-ira-into-5-billion-and-why-accredited-investors-are-now-eyeing-this-smartphone-disruptor">with $1,000 you can invest at just $0.30/share!</a></li>
</ul>
Image: Shutterstock

Personal Finance

Single Mom Discovers Care Facility Continued Receiving Her Son's $30/Month SSDI Payments, Even 8 Months After Reunification

As of June 17, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Regencell Bioscience Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>)</h3>
<ul class="wp-block-list">
<li>Regencell Bioscience's 38-for-one forward stock split officially took effect on Monday. The split, announced at the beginning of June and distributed on June 13, gave shareholders 37 additional shares for each one they already owned. The stock began trading on a split-adjusted basis on Monday. The company stated that the goal of the split was to improve liquidity and make its shares more accessible to investors. The company's stock jumped around 548% over the past month and has a <a href="https://www.benzinga.com/quote/RGC">52-week high of $83.60</a>.</li>
<li>RSI Value: 94&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>RGC Price Action: Shares of Regencell Bioscience gained 276.2% to close at $60.00 on Monday.</li>
<li>Edge Stock Ratings: 91.92 Momentum score with Value at 93.51.</li>
</ul>
<h3 class="wp-block-heading">Verve Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>)</h3>
<ul class="wp-block-list">
<li>On May 14, Verve Therapeutics reported a year-over-year increase for first-quarter EPS results. &#8220;2025 is off to a strong start with both clinical and regulatory progress. Last month, we reported exciting initial data from the Heart-2 clinical trial, which demonstrated that a single infusion of VERVE-102, a base editing medicine targeting PCSK9, was well-tolerated and led to compelling, dose-dependent reductions in LDL-C. These data, along with ongoing durability data of up to two years from our Heart-1 clinical trial, suggest a product profile that could fundamentally transform the journey for patients living with cardiovascular disease from decades of chronic care to a one dose future,&#8221; said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve Therapeutics. The company's stock gained around 43% over the past month and<a href="https://www.benzinga.com/quote/VERV"> has a 52-week high</a> of $9.30.</li>
<li>RSI Value: 88.1</li>
<li>VERV Price Action: Shares of Verve Therapeutics rose 1.8% to close at $6.27 on Monday.</li>
</ul>
<h3 class="wp-block-heading">SAGE Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>)</h3>
<ul class="wp-block-list">
<li>On June 16, Supernus Pharmaceuticals agreed to acquire Sage Therapeutics for $12.00 per share in cash, or an aggregate of up to approximately $795 million. The deal consideration includes $8.50 per share in cash (or an aggregate of approximately $561 million) plus one non-tradable contingent value right (CVR) collectively worth up to $3.50 per share in cash (or an aggregate of approximately $234 million). The company's stock gained around 32% over the past five days and has a <a href="https://www.benzinga.com/quote/SAGE">52-week high </a>of $13.46.</li>
<li>RSI Value: 86.2</li>
<li>SAGE Price Action: Shares of SAGE Therapeutics gained 35.4% to close at $9.07 on Monday.</li>
</ul>
Learn more about BZ Edge Rankings—click to see scores for other <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">stocks in the sector and see how they compare.</a>
Read This Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45948533/top-2-financial-stocks-that-may-plunge-in-q2"> Top 2 Financial Stocks That May Plunge in Q2</a></li>
</ul>

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

SAGE

VERV

Top 3 Health Care Stocks That Are Ticking Portfolio Bombs

A senior executive at Franklin Templeton has raised alarm that the European Union may fall behind in the global digital asset race as the pace of crypto regulation across the continent remains sluggish.
Speaking at the DigiAssets 2025 event, Catriona Kellas, International Legal Lead for Digital Projects at Franklin Templeton, warned that Europe could become a mere corridor between the rapidly advancing crypto markets of the United States and Asia, Decrypt <a href="https://decrypt.co/325528/eu-crypto-flyover-zone-franklin-templeton">reported</a>.
"Europe&#8217;s positioned well," she acknowledged, but emphasized that the region&#8217;s slower legislative process is a growing liability. 
Also Read: <a href="https://www.benzinga.com/crypto/25/06/45960131/coinfund-president-on-ai-tokens-depin-and-why-clear-rules-will-unleash-next-wave-of-crypto-adoption">Coinfund President On AI Tokens, DePIN, And Why Clear Rules Will Unleash Next Wave Of Crypto Adoption</a>
While once a pioneer in crypto regulation, the EU could find itself sidelined if it doesn't accelerate its response to the evolving landscape.
Kellas praised the momentum coming out of the U.S., calling it a driver of fresh urgency for European regulators. "There's a real danger," she said, "that delays in rulemaking allow more agile jurisdictions to leap ahead."
She noted that officials within the European Commission seem increasingly aware of this risk. 
In a recent meeting, Kellas highlighted how the term "competition," rarely uttered in past EU regulatory discussions surfaced as a focal point.
Talks around a possible upgrade to the EU's existing Markets in Crypto Assets (MiCA) framework are already underway. 
While Kellas described "MiCA 2" as not yet confirmed, she indicated that discussions around an update are gaining momentum.
Additionally, the EU's DLT pilot initiative, intended to provide a regulated environment for blockchain innovation, has been active for just a year, but Kellas said regulators are already working on improvements to ensure it remains effective and relevant.
Despite early concerns that MiCA 2 might introduce tighter restrictions, Kellas said optimism is growing. 
The sense is that European lawmakers are beginning to learn from developments in the U.S. and Asia-Pacific, potentially tempering overly rigid approaches.
Recent developments reinforce the industry's growing appetite for a European footprint. 
Both Coinbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) and Gemini are reportedly seeking licenses in Luxembourg and Malta, a move that would give them access across all 27 EU member states under the bloc's "passporting" regime.
However, that system has also triggered some anxiety among EU officials. 
Certain regulators worry about how quickly some member states are granting crypto licenses, potentially exposing the wider bloc to risks.
Kellas also suggested that global regulatory attitudes are beginning to shift. 
As digital assets become more integrated into the mainstream, it&#8217;s becoming harder for governments to revert to highly conservative postures. 
"It's difficult to put the genie back in the bottle," she said.
Beyond the written rules, she emphasized that informal or &#8220;soft&#8221; regulatory attitudes, such as institutional hesitation or bureaucratic caution, can be just as impactful as formal law. 
Increasingly, she said, regulators are being nudged by political leaders to move beyond traditional approaches and rethink their frameworks from the ground up.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45957567/bitcoin-ethereum-lead-1-9-billion-digital-asset-inflows-amid-global-tensions-coinshares-finds">Bitcoin, Ethereum Lead $1.9 Billion Digital Asset Inflows Amid Global Tensions, CoinShares Finds</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

COIN

Franklin Templeton Exec: Europe Stuck In The Slow Lane Of Crypto Regulation

Macro Economic Events

Econ #s

Economics

US Core Retail Sales (MoM) (May) -0.3% vs +0.2% Est.

USA Export Price Index (MoM) For May -0.9% Vs -0.1% Est.

Macro Notification

USA Retail Sales (MoM) For May -0.9% Vs -0.5% Est.

Health Care

Press Releases

Beyond Air Announces Agreements Expanding Global Distribution of LungFit® PH

Financing

NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy

Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site

NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer's Disease and Reinforcing Platform's Strength Across Neurological Disorders

Analyst Ratings

Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients' Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at Home

Management

NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board

NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism

Legal

Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections  Using gaseous Nitric Oxide (gNO)

Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and Webcast

Comments

Beyond Air

ニュース

最新ニュース Beyond Air (NASDAQ:XAIR) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル